Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Primary Peritoneal Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03648489
What this trial is testing

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinosarcoma+7 more
Imperial College London 134
Large-scale testing (Phase 3)Study completedNCT00483782
What this trial is testing

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Medical Research Council 1,520
Large-scale testing (Phase 3)Study completedNCT02631876
What this trial is testing

Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

Who this might be right for
Epithelial Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer+1 more
ImmunoGen, Inc. 366
Early research (Phase 1)Study completedNCT00959582
What this trial is testing

Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)

Who this might be right for
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Merck Sharp & Dohme LLC 42
Early research (Phase 1)Ended earlyNCT01243762
What this trial is testing

Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Who this might be right for
Neoplasms Malignant
Merck Sharp & Dohme LLC 47
Testing effectiveness (Phase 2)Looking for participantsNCT05503797
What this trial is testing

Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Who this might be right for
Cancer Harboring BRAF AlterationsHGGLGG+1 more
Fore Biotherapeutics 254
Large-scale testing (Phase 3)Ended earlyNCT01849874
What this trial is testing

MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

Who this might be right for
Low-grade Serous Ovarian CancerLow-grade Serous Fallopian Tube CancerLow-grade Serous Peritoneal Cancer
Pfizer 341
Early research (Phase 1)Study completedNCT01459380
What this trial is testing

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Who this might be right for
Ovarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous Carcinoma+5 more
National Cancer Institute (NCI) 41
Testing effectiveness (Phase 2)Study completedNCT02725489
What this trial is testing

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

Who this might be right for
Breast CancerOvarian CancerFallopian Tube Cancer+4 more
Mary Crowley Medical Research Center 13
Early research (Phase 1)Study completedNCT00083213
What this trial is testing

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
Cancer
Regeneron Pharmaceuticals 25
Early research (Phase 1)Ended earlyNCT03691376
What this trial is testing

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+9 more
Roswell Park Cancer Institute 4
Testing effectiveness (Phase 2)Study completedNCT02440425
What this trial is testing

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer
H. Lee Moffitt Cancer Center and Research Institute 42
Large-scale testing (Phase 3)Ended earlyNCT02718417
What this trial is testing

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

Who this might be right for
Ovarian Cancer
Pfizer 998
Not applicableStudy completedNCT02406235
What this trial is testing

Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer

Who this might be right for
Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer
AstraZeneca 710
Large-scale testing (Phase 3)Active Not RecruitingNCT05257408
What this trial is testing

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Who this might be right for
Ovarian NeoplasmFallopian Tube NeoplasmsPeritoneal Neoplasms
Corcept Therapeutics 381
Large-scale testing (Phase 3)Active Not RecruitingNCT03602859
What this trial is testing

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Who this might be right for
Ovarian NeoplasmsOvarian, Fallopian Tube and Primary Peritoneal Carcinoma
Tesaro, Inc. 1,400
Testing effectiveness (Phase 2)Ended earlyNCT01200797
What this trial is testing

SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin

Who this might be right for
Recurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity Cancer
National Cancer Institute (NCI) 19
Testing effectiveness (Phase 2)Study completedNCT05494580
What this trial is testing

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Who this might be right for
Ovarian CancerOvarian CarcinomaPlatinum-resistant Ovarian Cancer+2 more
Sun Yat-sen University 29
Testing effectiveness (Phase 2)Study completedNCT00318370
What this trial is testing

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms
Morphotek 58
Testing effectiveness (Phase 2)Study completedNCT00569673
What this trial is testing

Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group 71
Next Page